Ignite Creation Date:
2025-12-24 @ 1:03 PM
Ignite Modification Date:
2026-04-02 @ 5:03 PM
Study NCT ID:
NCT06566261
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-03
First Post:
2024-08-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ABA-101 in Participants With Progressive Multiple Sclerosis
Sponsor:
Abata Therapeutics
Organization:
Study Overview
Official Title:
A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis.
It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: